ARBs (angiotensin receptor blockers) can cause angioedema, but the risk is very low. In a large meta-analysis of randomized trials, the weighted incidence of angioedema with ARBs was 0.11%, compared to 0.07% with placebo and 0.30% with ACE inhibitors. So while ARBs do carry a small risk, it’s roughly a third of the risk seen with ACE inhibitors and only slightly above what occurs with a sugar pill.
How ARB Angioedema Differs From ACE Inhibitor Angioedema
ACE inhibitors cause angioedema through a well-understood mechanism. They block an enzyme that breaks down bradykinin, a substance that dilates blood vessels and causes tissue swelling. When bradykinin builds up in the body, it can trigger swelling in the lips, tongue, throat, or face.
ARBs work differently. They block the receptor where angiotensin II (a hormone that raises blood pressure) attaches, and they don’t directly interfere with bradykinin breakdown. For this reason, angioedema wasn’t originally expected as a side effect at all. The mechanism behind ARB-related angioedema is still not fully understood, but researchers believe it happens through an indirect chain of events. When ARBs block the angiotensin II receptor, angiotensin II levels rise. That excess angiotensin II may stimulate a second type of receptor that, in turn, reduces the activity of the enzyme that breaks down bradykinin. The end result is the same: more bradykinin circulating in the body, leading to swelling. There’s also evidence that losartan specifically may directly activate a bradykinin receptor on its own.
When Symptoms Typically Appear
One of the trickiest aspects of this condition is timing. In a study of 51 patients who developed angioedema from blood pressure medications in this drug class, the average time from starting the medication to the first episode was 1.8 years. Only 25% of patients developed symptoms within the first month, and just 12% experienced angioedema in the first week. This long delay means many people (and their doctors) don’t immediately connect the swelling to a medication they’ve been taking for months or years without any problems.
Swelling most commonly affects the face, lips, tongue, and throat. Episodes can range from mild facial puffiness to severe throat swelling that makes breathing difficult. Most people who show up to an emergency department with angioedema are discharged home, and less than 1% require a breathing tube. But severe cases do happen, which is why any sudden unexplained swelling of the face or throat while taking an ARB warrants immediate medical attention.
Who Is at Higher Risk
The risk factors for ARB-related angioedema overlap heavily with those identified for ACE inhibitor angioedema. The most consistently identified risk factors include:
- African ancestry: People of African descent have a 3 to 5 times higher frequency of angioedema from medications in this class. One study found that Black genetic ancestry carried an adjusted odds ratio of 15.4 for developing ACE inhibitor angioedema compared to controls.
- Older age: People 65 and older appear more vulnerable.
- Female sex: Several studies have found women at higher risk, though at least one study pointed to male sex instead.
- Allergic conditions: A history of seasonal allergies, allergic rhinitis, or atopic dermatitis has been linked to increased risk.
- Calcium channel blocker use: Taking a calcium channel blocker alongside a blood pressure medication in this class was a significant independent risk factor in at least one large study.
Does the Specific ARB Matter?
There’s evidence that not all ARBs carry the same risk. An analysis of the FDA’s adverse event reporting system found that losartan had the highest reporting proportion for skin-related side effects (which includes angioedema) among all ARBs studied. Using losartan as the baseline, valsartan, irbesartan, candesartan, telmisartan, and olmesartan all had significantly lower rates of skin-related adverse events. Olmesartan showed the lowest rates overall. This fits with research showing that losartan may directly activate a bradykinin receptor, something not demonstrated with other ARBs. If you’ve had a skin reaction to losartan specifically, switching to a different ARB may be a reasonable option to discuss with your prescriber.
Switching From an ACE Inhibitor to an ARB
This is one of the most common clinical questions around this topic. If you developed angioedema on an ACE inhibitor like lisinopril or enalapril, is it safe to switch to an ARB? Early estimates suggested the risk of angioedema recurring on an ARB was between 3.5% and 9.4%. But an updated meta-analysis that incorporated data from a large clinical trial brought that estimate down to about 2.5%, with the confidence interval spanning from 0% to 6.6%. Statistically, there was no significant difference in angioedema rates between ARBs and placebo in patients with a history of ACE inhibitor angioedema.
In practice, this means that switching to an ARB after ACE inhibitor angioedema is generally considered acceptable, though not entirely without risk. For people whose angioedema was severe (involving the throat or airway), many clinicians prefer to avoid the entire drug class and use alternatives like calcium channel blockers or other blood pressure medications that work through completely different pathways.
How ARB Angioedema Is Treated
The first and most important step is stopping the ARB. Because ARB-related angioedema is driven by bradykinin rather than histamine, the standard treatments for allergic reactions (antihistamines, steroids, epinephrine) have limited effectiveness. They’re still commonly given in emergency settings, but the response is often minimal.
For severe or treatment-resistant episodes, therapies borrowed from hereditary angioedema management have shown promise. A drug that blocks the bradykinin receptor has been recommended as first-line therapy for this type of angioedema by France’s National Center for Angioedema, and case reports support its use for faster symptom relief. Plasma infusions, which supply the enzyme that breaks down bradykinin, have also been used successfully in cases that don’t respond to standard treatment. However, no formally approved treatment algorithm exists in the United States specifically for this type of drug-induced angioedema.
After the medication is stopped, most people see their angioedema resolve completely, though it can take days to fully clear. Recurrent episodes after discontinuation are rare and should prompt evaluation for other underlying causes of angioedema.